Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma in China: a Real-world Study
Latest Information Update: 07 Jul 2021
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib
- Indications Liver cancer
- Focus Adverse reactions
- 07 Jul 2021 New trial record